The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial.
 
Hironori Ishigami
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Yoshiyuki Fujiwara
No Relationships to Disclose
 
Ryoji Fukushima
Research Funding - Aventis Pharma (Inst); Chugai Pharma (Inst); Nutrisystem (Inst); Taiho Pharmaceutical (Inst)
 
Atsushi Nashimoto
No Relationships to Disclose
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Haruhiko Imamoto
No Relationships to Disclose
 
Motohiro Imano
No Relationships to Disclose
 
Yasuhiro Kodera
Honoraria - Ajinomoto; Bayer; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Merck; MSD; Olympus; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - abbott Japan (Inst); Abbvie (Inst); Ajinomoto (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Covidien (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Japan Blood Products Organization (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); KCI (Inst); Lilly Japan (Inst); Merck (Inst); Mitsubishi Tanabe Pharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Pharmaceutical (Inst); Yoshindo (Inst)
 
Yoshikazu Uenosono
Research Funding - Chugai Pharma (Inst)
 
Kenji Amagai
Consulting or Advisory Role - Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shigenori Kadowaki
Research Funding - Lilly (Inst); Taiho Pharmaceutical (Inst)
 
Hiroto Miwa
No Relationships to Disclose
 
Takuhiro Yamaguchi
No Relationships to Disclose
 
Hironori Yamaguchi
No Relationships to Disclose
 
Toshiaki Watanabe
Research Funding - Ajinomoto (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kaken Pharmaceutical (Inst); Kyorin (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Mitsubishi Tanabe Pharma (Inst); Miyarisan pharmaceutical (Inst); Otsuka (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Joji Kitayama
Research Funding - Taiho Pharmaceutical (Inst)